Group 1 - The cannabis industry, including multi-state operator Cresco Labs, is facing significant challenges such as black- and gray-market competition, limited access to financial services, and high taxation [1][2] - Cresco Labs' stock performance has been poor, with a $1,000 investment in the stock shrinking to approximately $200 over the past five years, while the S&P 500 index would have grown to $1,878 in the same period [2] - The legal status of cannabis in the U.S. is complicated, with federal illegality contrasted by varying state laws, leading to a patchwork of legalization across the country [4] Group 2 - There is ongoing lobbying for federal rescheduling of marijuana, but it is not a priority for lawmakers, leaving companies like Cresco in a survival mode [5] - Cresco Labs is experiencing declining revenue and ongoing challenges with profitability, although it has recently refinanced a $325 million credit facility and holds $147 million in cash and equivalents [6]

NEW YORK, Aug. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities you ...

I am an individual investor with over five years of experience in personal investing, holding a PhD in Economics from UCEMA. My investment approach focuses on value companies with solid long-term potential. I share my knowledge with the community by offering analysis to support individual investors. My articles reflect personal opinions and do not constitute financial advice.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to init ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Stanley Druckenmiller and Bill Ackman were buying shares of these tech giants in the second quarter.Buying and holding shares of the best businesses in the world is the easiest way to build wealth over the long term. Some of the largest, most profitable companies in the world also just happen to be in a prime position to benefit from global adoption of artificial intelligence (AI), which is expected to add $15.7 trillion to the global economy by 2030, according to PwC.Investors wondering where to place thei ...

Core Insights - Acoramidis has shown a significant reduction in cardiovascular mortality (CVM) risk by 44% over 42 months post-randomization, establishing a new standard for outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [1][2] - The treatment also demonstrated a 46% hazard reduction in the composite outcome of CVM or first cardiovascular hospitalization (CVH) over the same period [1] - Acoramidis has been approved by the U.S. FDA as Attruby and by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency as BEYONTTRA [1][5] Efficacy and Clinical Benefits - In the ATTRibute-CM study, acoramidis exhibited the fastest benefit observed in any Phase 3 study for ATTR-CM, with significant improvements noted as early as 3 months [1] - At Month 30, there was a 42% reduction in composite all-cause mortality (ACM) and recurrent CVH events compared to placebo [1] - A 50% reduction in the cumulative frequency of CVH events was also reported at Month 30 relative to placebo [1] - Acoramidis treatment resulted in improved or stable NT-proBNP levels in approximately 50% of participants at Month 30, compared to fewer than 20% in the placebo group, indicating meaningful clinical improvement [3] - The treatment also showed a greater proportion of patients with stable or improved NAC Stage at Month 30 compared to placebo, suggesting better disease stabilization [3] Regulatory and Commercial Developments - BridgeBio Pharma has entered into an exclusive licensing agreement with Bayer Consumer Care AG for the commercialization of BEYONTTRA in Europe [4] - Future medical meetings are planned to present additional data on the benefits of Attruby for ATTR-CM patients [5]

I’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve around is momentum.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

Qualcomm's bold bets on AI, automotive, and IoT could transform this dividend-paying chip giant into one of tech's biggest growth stories.Qualcomm (QCOM -0.11%) is no longer just a smartphone chipmaker -- it's expanding into AI, automotive, and IoT with bold acquisitions like Alphawave. With analysts seeing 41% upside, Qualcomm may be one of the most overlooked growth and dividend plays today.Stock prices used were the market prices of Aug. 26, 2025. The video was published on Aug. 29, 2025. ...

Group 1 - The Value Lab focuses on long-only value investment strategies, aiming to identify mispriced international equities with a target portfolio yield of approximately 4% [1][2] - The Value Lab has successfully navigated international markets over the past five years, indicating a strong performance in value investing [1] - The Valkyrie Trading Society consists of analysts who share high-conviction investment ideas that are expected to yield non-correlated and outsized returns in the current economic environment [3] Group 2 - The Value Lab provides members with a comprehensive service that includes real-time portfolio updates, 24/7 chat support, regular market news reports, and feedback on stock ideas [2] - The focus of the investment strategies is on downside-limited opportunities within developed markets [3]

If you are a dividend investor, you can buy this exchange-traded fund and let someone else do all the hard work of stock picking for you.Picking stocks is hard work -- and your job isn't done after making the buy decision. Then you have to keep track of the companies you've chosen to own to make sure that the reasons why you picked them continue to apply. However, dividend investors don't have to put in all of that work if they don't want to. All they have to do is buy the Schwab US Dividend Equity ETF (SCH ...